[Skip to Navigation]
Brief Report
November 10, 2021

Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis

Author Affiliations
  • 1Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut
  • 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
  • 3Department of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut
JAMA Dermatol. Published online November 10, 2021. doi:10.1001/jamadermatol.2021.4084
Key Points

Questions  Is Janus kinase (JAK) inhibition effective for persistent erythema multiforme (PEM), and what are the important molecular targets?

Findings  Four patients with PEM treated with JAK inhibition experienced marked clinical improvement, while RNA sequencing and proteomic evaluation in a single patient before and during treatment revealed that interferon gamma (IFN-γ) and interleukin 15 (IL-15) were both overproduced in erythema multiforme and modulated by tofacitinib. In these and other PEM cases (total, 12 patients), RNA in situ hybridization confirmed significant upregulation of IFN-γ and IL-15.

Meaning  The findings of this case series study suggest that cytotoxic responses in patients with PEM may be promoted by IFN-γ and IL-15 and may be controlled with JAK inhibition.

Abstract

Importance  Persistent erythema multiforme (PEM) is poorly understood and lacks effective therapies other than glucocorticoids.

Objective  To report outcomes following treatment of PEM with Janus kinase (JAK) inhibition and to elucidate cytokine drivers of erythema multiforme (EM).

Design, Setting, and Participants  This was a retrospective case series of 4 patients with PEM treated with tofacitinib and/or upadacitinib in 2015 to 2021 at the dermatology clinics of 2 major tertiary referral centers. Four consecutive patients with PEM refractory to multiple treatment approaches were treated. In 1 patient, skin biopsy specimens were obtained for RNA sequencing and proteomic analysis before and during treatment. Molecular findings were validated through RNA in situ hybridization analysis of cytokine expression in biopsy specimens from a total of 12 patients with EM (3 treated with tofacitinib in this study and 9 historic samples).

Interventions  Treatment with tofacitinib, 5 to 10 mg, twice daily or upadacitinib, 15 mg, once daily.

Main Outcomes and Measures  Change in PEM activity was assessed in all 4 patients treated with a JAK inhibitor. Median (range) follow-up was 20.5 months (10.0-36.0 mo).

Results  The study population of 4 female patients had a mean (SD) age of 46.2 (13.7) years and a mean (SD) disease duration of 21.75 (11.30) years. Marked clinical improvement was noted in all 4 patients. In 1 patient with a robust improvement following treatment with tofacitinib, RNA sequencing identified interferon gamma (IFN-γ) and interleukin 15 (IL-15) as cytokines with activity both highly upregulated at baseline in lesional skin and subsequently suppressed following tofacitinib treatment. Measurement of IFNG- and IL15-positive cells in additional EM biopsy specimens of 12 patients showed significant upregulation of IFNG (8.72 cells per mm; 95% CI, 2.60-14.84) and IL15 (14.13 cells per mm; 95% CI, 0.14-28.11) compared with normal skin (P = .008 and P = .045, respectively).

Conclusions and Relevance  The results of this case series study suggest that JAK inhibition may be effective in treating PEM and that IFN-γ and IL-15 may be important cytokine mediators of the disease.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×